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Abstract
Background: In the absence of a HLA-matched related or matched unrelated donor, allogeneic stem cell
transplantation (allo-SCT) from mismatched unrelated donors or haploidentical donors are potential alternatives for
patients with acute leukemia with an indication to allo-SCT. The objective of this study was to compare the
outcome of allo-SCT from T cell-replete haploidentical (Haplo) versus matched (MUD 10/10) or mismatched
unrelated donor at a single HLA-locus (MMUD 9/10) for patients with acute leukemia in remission.
Methods: Two hundred sixty-five adult patients with de novo acute leukemia in first or second remission that
received a Haplo-SCT between January 2007 and December 2013 were compared with 2490 patients receiving a
MUD 10/10 and 813 receiving a MMUD 9/10. Propensity score weighted analysis was conducted in order to control
for disease risk imbalances between the groups.
Results: The weighted 3-year non-relapse mortality and relapse incidence were 29 and 30% for Haplo, 21 and 29%
for MUD 10/10, and 29 and 25% for MMUD 9/10, respectively. The weighted 3-year leukemia-free survival (LFS) and
overall survival (OS) were 41 and 46% for Haplo, 50 and 56% for MUD 10/10, and 46 and 48% for MMUD 9/10,
respectively. Using weighted Cox model, both LFS and OS were significantly higher in transplants from MUD 10/10
compared from those in Haplo but not different between transplants from MMUD 9/10 and Haplo. The type of
donor was not significantly associated with neither acute nor chronic graft-versus-host disease.
Conclusions: Patients with acute leukemia in remission have better outcomes if transplanted from a MUD 10/10.
We did not find any significant difference in outcome between transplants from MMUD 9/10 and Haplo,
suggesting that both can be equally used in the absence of a 10/10 MUD.
Key point 1: Better outcomes using fully (10/10) matched unrelated donor for allo-SCT in acute leukemia in
remission.
Key point 2: Similar outcomes after allo-SCT from unmanipulated haploidentical graft or mismatched (9/10)
unrelated donor in acute leukemia in remission.
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Background
Allogeneic stem cell transplantation (allo-SCT) repre-
sents the only possible cure for most adult acute leuke-
mias (AL). HLA-matched related (MRD) or unrelated
donors (MUD) are usually considered the preferable
donors, but they are not available for all the patients
with an indication for allo-SCT. In the absence of a
HLA-matched donor, allo-SCT from mismatched unre-
lated donors (MMUD), cord blood units (CB), or haploi-
dentical (Haplo) donors are potential alternatives.
A Haplo donor is available for virtually all AL patients,
enabling minimal delay and access to repeated stem cell
(SC) donations or donor lymphocyte infusions, if needed.
These are the main reasons for the increasing numbers of
Haplo-SCT for AL in recent years. Unmanipulated (non
ex vivo T-depleted) grafts from Haplo donors, in compari-
son to T-depleted ones, result in lower incidence of
serious infections due to faster immune reconstitution
and stronger graft versus leukemia effect [1, 2]. In
addition, the introduction of more effective regimens for
graft-versus-host disease (GvHD) prophylaxis for T-
replete Haplo-SCT contributed to reduce GvHD incidence
and to increase the use of unmaniplated grafts for the
Haplo setting [3–10].
Recently, several reports have shown comparable
allo-SCT outcomes between Haplo and historical
MRD, MUD, and MMUD series [11–15]. However,
these are mostly but one [14] single center studies
with limited number of patients [11, 12, 15] in vari-
ous disease categories and status. For these reasons,
we decided to perform a large, registry-based study,
using the European Society of Bone Marrow Trans-
plantation (EBMT)-Acute Leukemia Working Party
(ALWP) registry, comparing T-replete Haplo-SCT to
transplants from MUD and MMUD for AL patients
in first or second remission.
Methods
In order to be included in the study, the patients had to
fulfill all the following criteria: age ≥18 years; de novo
AL; disease status at transplant: complete remission 1
(CR1) or 2 (CR2); family donor with host/donor number
of HLA mismatches ≥2 (Haplo), or MUD 10/10 or
MMUD 9/10 (patients and donors should have HLA A,
B, C, and DRB1 and DQB1 allelic typing performed);
peripheral blood (PB) or bone marrow (BM) or both as
source of SC; no ex vivo T cell depletion; and first allo-
SCT (previous autologous SCT was allowed). All pa-
tients underwent transplantation between January 2007
and December 2013. We were able to verify the inclu-
sion criteria for 265 Haplo-SCT, 2490 MUD 10/10-SCT,
and 813 MMUD 9/10-SCT. This was a retrospective
multicenter analysis. Data were provided and approved
for this study by the ALWP of the EBMT group registry.
The EBMT is a non-profit, scientific society representing
more than 600 transplant centers mainly in Europe. The
EBMT promotes all activity aiming to improve stem cell
transplantation or cellular therapy, which includes regis-
tering all the activity relating to stem cell transplants.
Data are entered, managed, and maintained in a central
database with internet access; each EBMT center is
represented in this database. There are no restrictions
on centers for reporting data, except for those required
by the law on patient consent, data confidentiality, and
accuracy. Quality control measures included several
independent systems: confirmation of validity of the
entered data by the reporting team, selective comparison
of the survey data with minimum essential data A
(MED-A) data sets in the EBMT registry database,
cross-checking with the National Registries, and regular
in-house and external data audits. Since 1990, patients
have provided informed consent authorizing the use of
their personal information for research purposes.
Definitions and statistical analysis
The primary endpoints were leukemia-free survival
(LFS) and overall survival (OS). The secondary end-
points were engraftment, acute and chronic GVHD
(aGVHD and cGVHD), relapse incidence (RI), non-
relapse mortality (NRM), and graft-versus-host relapse-
free survival (GRFS) [16]. LFS was defined as time to
death or relapse, whichever came first. OS was defined
as time to death from all causes. NRM was defined as
death without evidence of relapse. Engraftment was
defined as the first of three consecutive days with an
absolute neutrophil count > 0.5 × 109/L. Acute GVHD
was graded according to the modified Seattle-Glucksberg
criteria [17] and cGVHD according to the revised Seattle
criteria [18].
We used propensity scores (PS) weighting to control
for pre-treatment imbalances on observed variables. The
following factors were included in the PS model: patient
age, time from diagnosis to transplantation, year of
transplant, diagnosis (AML versus ALL), status at tra-
nsplant (CR1 versus CR2), cytogenetics group, donor/
patient CMV serology, conditioning (RIC versus MAC),
and sex matching (female donor to male recipient versus
other). The estimation of propensity score was performed
using generalized boosted models [19].
As the study question was whether Haplo could replace
10/10 or 9/10 MUD, we weighted the groups receiving
either MUD 10/10- and MMUD 9/10-HSCT to match the
characteristics of patients receiving Haplo-SCT, by esti-
mating the average treatment effect among the treated
(ATT); Haplo-HSCT being the treated group. The ATT
weights equal one for Haplo-HSCT, and it equals the ratio
of the propensity score to one minus the propensity score
in the two UD-HSCT groups. Therefore, UD patients that
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were significantly different from average haplo-grafted pa-
tients had a low contribution in the comparisons. We
checked the balance between the groups looking to ATT
weighted means. Then, we used pairwise ATTs to fit the
weighted Kaplan-Meier and Cox models separately for
Haplo- versus MUD 10/10-HSCT and Haplo- versus
MMUD 9/10-HSCT.
The type I error rate was fixed at 0.05 for determin-
ation of factors associated with time to event. Analyses
were performed using the R statistical software version
3.2.3 (R Development Core Team, Vienna, Austria);
propensity score analysis was performed using the mnps
function of the Twang package and weighted analyses
using the survey package [20].
Results
Patients’ and donors’ characteristics
Patient’s and host/donors’ characteristics are showed in
Table 1. Regimens, stem cell source, and GvHD prophy-
laxis are described in Table 2. Anti-thymocyte globulin
(ATG) was used for in vivo T cell depletion in 120/265
Haplo (45%), 1457/2490 (59%) 10/10 MUD, and 550/813
(82%) 9/10 MMUD. Campath was used in 6/265 Haplo
(1%), 302/2490 (12%) MUD, and 124/813 (18%) MMUD.
PT-Cy was used in 107/265 Haplo (40%), 27/2490 (1%)
MUD, and 12/813 (1%) MMUD. Among patients receiv-
ing a MMUD 9/10, 204 (25%) were mismatched in locus
A, 115 (14%) in locus B, 275 (34%) in locus C, 62 (8%)
in locus DRB1, and 157 (19%) in locus DQB1. Allelic
typing for locus A, B, C, DRB1, and DQB1 was available
for all patients and donors.
Engraftment
The 30-day CI of engraftment was 95% (92–97%) for
Haplo, 97% (93–98%) for MUD 10/10, and 92% (88–
95%) for MMUD 9/10. In weighted Cox model, CI of
engraftment resulted to be lower in Haplo versus MUD
10/10 (p = 0.015) but not different between Haplo and
MMUD 9/10 (p = 0.62).
Non-relapse mortality, acute and chronic GvHD
The weighted CI of NRM at 3 years was 29% (23–34%),
21% (15–26%), and 29% (23–35%) for Haplo , MUD 10/
10, and MMUD 9/10 (Fig. 1a), respectively. In weighted
Cox model, NRM was lower in MUD 10/10 as compared
in Haplo, but not different from that in MMUD 9/10
(Table 3). The percentage of grades II–IV aGvHD was
28% (22–33%), 25% (18–31%), and 27% (21–33%) for
Haplo, MUD 10/10, and MMUD 9/10, respectively. The
frequency of grades III–IV aGvHD was 10% (6–13%) for
Haplo, 7% (3–10%) for MUD 10/10, and 11% (6–15%)
for MMUD 9/10. The 3-year CI of overall cGvHD and
extensive cGvHD was 34% (28–40%) and 15% (10–20%),
40% (33–47%) and 22% (15–28%), and 33% (26–39%)
and 18% (12–23%) for Haplo, MUD 10/10, and MMUD
9/10, respectively. Neither grades II–IV aGvHD nor
chronic GvHD incidences differed between Haplo versus
MUD 10/10 and Haplo versus MMUD 9/10 in weighted
Cox analysis (Table 3).
Relapse incidence
The weighted CI of relapse at 3 years was 30% (24–
35%), 29% (22–35%), and 25% (19–31%) for Haplo,
MUD 10/10, and MMUD 9/10, respectively (Fig. 1b).The
type of donor was not a predictive factor for relapse in
weighted Cox model (Table 3).
LFS, OS, and GRFS
The median follow-up among survivors was 34 (range,
3–84) months for Haplo, 36 (range, 1–103) for MUD
10/10, and 36 (range, 1–102) for MMUD 9/10, respect-
ively. The weighted probability of LFS at 3 years was
41% (35–48%), 50% (43–58%), and 46% (39–53%) for
Haplo, 10/10 MUD, and 9/10 MMUD, respectively
(Fig. 2).The weighted probability of 3-year OS was 46%
(40–53%), 56% (49–64%), and 48% (41–56%) (Fig. 2).The
3-year GRFS was 33% (28–40%), 36% (29–44%), and
34% (28–41%) for Haplo, 10/10 MUD, and 9/10 MMUD,
respectively (Fig. 2). In the weighted Cox analysis, LFS
and OS resulted to be better for MUD 10/10 compared
with Haplo, but no statistical difference comparing
Haplo with MUD 9/10. No statistical differences were
found in GRFS according to the type of donor in the
weighted Cox analysis (Table 3).
Discussion
In the absence of a MRD for allo-SCT in acute leukemia,
the ideal donor still remains to be determined. The
current report represents a large registry study compar-
ing the outcome between transplants from Haplo and
MUD 10/10 or MMUD 9/10 for adult patients with de
novo AL in remission.
As a recent ALWP-EBMT survey on unmanipu-
lated haploidentical transplantation in AL showed a
lower incidence of aGvHD in patients receiving PT-
Cy but no significant statistical differences in either
LFS or OS [21], in our study we included all the
non T-depleted Haplo-SCT registered in the EBMT
database.
Previous reports described worse outcomes after
MMUD in comparison to MUD [22–26], and this find-
ing was in accordance to our preliminary data and to a
recent ALWP publication [27].
We did not find any differences in terms of LSF and
OS in the 813 MMUD-SCT according to HLA-DQ
mismatch in univariate analysis (p = 0.35). Therefore, we
decided to compare separately MUD 10/10 and MMUD
9/10 transplants with Haplo.
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Table 1 Patients’ and host/donor characteristics
Haplo MUD10/10 MMUD 9/10 MUD 10/10 vs Haplo MMUD 9/10 vs Haplo
No. 265 2490 813
Follow-up 34.2 (3–84) 35.7 (1–103) 35.8 (1–102) 0.93 0.72
Age 42.8 (18–75) 47.0 (18–76) 44.8 (18–71) <10–3 0.017
Year of Tx 2011 (07–13) 2010 (07–13) 2010 (07–13) <10–3 <10–3
Diagnosis to transplant 260 days (82–5784) 196 days (71–5793) 223d (73–4452) <10–3 0.016
Diagnosis
AML 176 1645 510
66% 66% 63%
ALL 89 845 303 0.90 0.28
34% 34% 37%
Disease status
CR1 159 1901 580
60% 76% 71%
CR2 106 589 233 <10–3 0.001
40% 24% 29%
Patient sex
Male 155 1344 442
58% 54% 54%
Female 110 1146 371 0.16 0.24
42% 46% 46%
Donor sex
Male 139 1782 490
52% 72% 61%
Female 126 690 312 <10–3 0.013
48% 28% 39%
Female to male
No 191 2186 659
72% 88% 82%
Yes 74 286 143 <10–3 <10–3
28% 12% 18%
CMV neg to neg
No 225 1673 577
86% 69% 73%
Yes 36 754 212 <10–3 <10–3
14% 31% 27%
Cytogenetics
Good 29 261 68
11% 10% 8%
Intermediate 168 1398 446
63% 56% 55%
Poor 68 831 299 0.04 0.004
26% 33% 37%
See text for abbreviations. Cytogenetic risk at diagnosis for AML: good t(8;21), inv16 or t(16;16); poor monosomy/deletion 5 or 7, abnormalities 11q23, complex
karyotype (≥3 abnormalities); intermediate all the others. Cytogenetic risk at diagnosis for ALL: adverse t(9;22) or t(4;11), intermediate all the others
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The 30-day CI of engraftment proved to be lower in
Haplo than in MUD 10/10 but not different between
Haplo and MMUD 9/10. In addition to the type of
donor, the number and type of chemotherapy cycles pre-
transplant and/or early post-transplant infections, in
particular viral, could have had an impact on differences
in engraftment. A lower incidence of engraftment in
Haplo compared in UD was previously reported in both
reduced intensity [14] and myeloablative conditioning
transplants [15].
Notably, we did not find any difference in the inci-
dence of either aGvHD > II or cGvHD according to
donor type in line with similar comparisons in litera-
ture. This was true also for grades III–IV aGvHD and
extensive cGvHD. In the recent report comparing
Haplo using PT-Cy to UD from the Center for Inter-
national Blood and Marrow Transplant Research
(CIBMTR), the authors describe a lower incidence of
acute and cGvHD in Haplo on univariate analysis
[14], but most of the Haplo were performed using
BM as stem cell source, and most of the UD using
PB without receiving any in vivo T cell depletion. Of
note, they did not find any difference in the 3-year
cGvHD incidence according to donor type when ana-
lyzing only patients receiving BM. The role of stem
cell source as risk factor for cGvHD after Haplo-SCT
remains to be determined. While some reports do not
show any difference in terms of cGvHD between PB
and BM in haploidentical transplantations using PT-
Cy [28, 29], a recent comparison from CIBMTR
Haplo
a b
MUD 10/10
MMUD 9/10
Fig. 1 Weighted CI of relapse and non-relapse mortality according to donor type. a Weighted CI of relapse. b Weighted CI of NRM
Table 2 Conditioning regimens, stem cell source, and in vivo T cell depletion
No. Haplo MUD10/10 MMUD 9/10 MUD 10/10 vs Haplo MMUD 9/10 vs Haplo
265 2490 813
Conditioning
MAC 138 1460 489
52% 59% 60%
RIC 127 1018 322 0.03 0.02
48% 41% 40%
Stem cell source
BM 141 473 141 <10–4 <10–4
53% 19% 17%
PB 124 2017 672
47% 81% 83%
In vivo T cell depletion
No 38 720 137 <10–4 <10–4
15% 29% 17%
ATG 120 1743 664
45% 70% 82%
Pt-Cy 107 27 12
40% 1% 1%
See text for abbreviations
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concludes for a high incidence of cGvHD using PB
instead of BM [30]. Notable, in the context of UD,
cGvHD has been shown to be higher using PBSC [31]
especially if not using in vivo T cell depletion [32].
The 3-year NRM was higher using Haplo (29%)
compared with MUD 10/10 (21%) but identical com-
pared with MMUD (29%), in contrast with other re-
ports on similar comparisons where the authors did
not find any difference [11–15]. This higher NRM in
Haplo compared in MUD 10/10 could be in part due
to the use of in vivo T cell depletion other than PT-
Cy in the 45% of our Haplo [33]. In addition to the
type of in vivo T cell depletion, also, differences in
conditioning regimens could explain our finding [14].
Patients’ comorbidities, mostly unknown in restros-
pective study, could also have influenced NRM. The
3-year CI of relapse was not different between the
three groups.
The lower NRM in MUD 10/10 resulted in both a
higher 3-year LFS and OS compared in Haplo but
no difference in GRFS. No differences in either OS,
LFS, or GRFS were observed between Haplo and
MMUD 9/10. Analyzing separately patients with
AML and ALL, we found no differences of GRFS in
Haplo compared in MUD 10/10 and compared in
MMUD 9/10, higher LFS and OS in MUD 10/10
compared in Haplo but no differences between
Haplo and MMUD 9/10 in terms of LFS and OS
(Additional file 1).
Based on these results, we can assert that patients with
acute leukemia in remission showed better outcomes if
transplanted from a MUD 10/10. We did not find any
significant difference in outcome between MMUD 9/10
and Haplo, suggesting that both can be equally used in
the absence of a MUD 10/10 and that other factors, such
as urgency of transplant and center expertise should dic-
tate the choice between these two alternative donor
sources.
Ongoing and future prospective clinical studies,
including transplants from CBU, will ultimately be re-
quired to determine the best alternative donor for adult
AL patients who lack an HLA-matched sibling one.
Years post transplantation Years post transplantation
ba
Fig. 2 Weighted probability of leukemia-free survival and overall survival according to donor type. a Weighted probability of leukemia-free
survival. b Weighted probability of overall survival
Table 3 Weighted Cox model for NRM, RI, LFS, OS, and GRFS
3-year MUD 10/10 vs Haplo p MMUD 9/10 vs Haplo p
HR (95%CI) HR (95%CI)
Day 30 PMN engraftment 0.845 (0.740-0.968) 0.015 0.961 (0.819-1.127) 0.623
II–IV aGvHD 0.8877 (0.6777–1.163) 0.387 1.0433 (0.7716–1.411) 0.783
III–IV aGvHD 0.673 (0.4334–1.045) 0.078 1.184 (0.7221–1.942) 0.5027
cGVHD all 1.0763 (0.8474–1.367) 0.547 0.9555 (0.7264–1.257) 0.745
Extensive cGvHD 1.483 (0.9890–2.224) 0.057 1.288 (0.8342–1.990) 0.253
NRM 0.6363 (0.4838–0.8369) 0.0012 0.9905 (0.7009–1.3997) 0.957
RI 0.8624 (0.6668–1.115) 0.259 0.8426 (0.6312–1.125) 0.245
LFS 0.7487 (0.6229–0.8998) 0.002 0.9164 (0.7296–1.1511) 0.45
OS 0.7074 (0.5824–0.8591) 0.0005 0.9300 (0.7302–1.1844) 0.56
GRFS 0.8804 (0.7433–1.043) 0.14 1.0313 (0.8370–1.271) 0.772
See text for abbreviations
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Abbreviations
AL: Acute leukemia; ALL: Acute lymphoblastic leukemia; AML: Acute myeloid
leukemia; ATG: Anti-thymocyte globulin; ATT: Average treatment effect
among the treated; BM: Bone marrow; CB: Cord blood;
CMV: Cytomegalovirus; CR: Complete remission; GRFS: Graft-versus-host
relapse-free survival; GVHD: Graft-versus-host disease (acute aGvHD or
chronic cGvHD); HAPLO: Haploidentical donor; LFS: Leukemia-free survival;
MAC: Myeloablative conditioning regimen; MMUD: Mismatched unrelated
donor; MRD: Matched related donor; MUD: Matched unrelated donor;
NRM: Non-relapse mortality; OS: Overall survival; PB: Peripheral blood;
PMN: Polymorphonuclear cells; PS: Propensity score; PT-Cy: Post-transplant
cyclophosphamide; RI: Relapse incidence; RIC: Reduced intensity
conditioning regimen; SC: Stem cell; SCT: Stem cells transplantation;
TX: Transplant
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